Molecular Biomarkers for Glaucoma
- PMID: 33133776
- PMCID: PMC7597904
- DOI: 10.1007/s40135-019-00213-0
Molecular Biomarkers for Glaucoma
Abstract
Purpose of review: This article summarizes the current studies on molecular biomarkers with potential implications in diagnosis, prognosis, and response to treatment in patients with glaucoma.
Recent findings: Important advances have occurred in the understanding of the pathogenesis of glaucomatous neurodegeneration. Protein biomarkers associated with inflammatory, neurodegenerative, and other molecular pathways have been described in glaucoma patients in tear film, aqueous fluid, vitreous fluid, and serum, however, we are still far from having a clear picture of the whole molecular network that relates to the disease and its implications in clinical use.
Summary: Although more studies are needed, current and emerging molecular biomarkers candidates in glaucoma may eventually transition into clinical use and contribute to outline the concept of precision medicine and precision health in glaucoma.
Keywords: Glaucoma; biomarkers; optic nerve degeneration.
Conflict of interest statement
Compliance with Ethics Guidelines Conflict of Interest Gala Beykin and Jeffrey L. Goldberg each declare no potential conflicts of interest.
References
-
- Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109(8):1090–5. - PubMed
-
- Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical pharmacology and therapeutics. 2001;69(3):89–95. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials